Pseudocholinesterase deficiency: A comprehensive review of genetic, acquired, and drug influences

AANA Journal

Volumn 78, Issue 4, 2010, Pages 313-320

  Soliday, Flanna K ^a,b   Conley, Yvette P ^b   Henker, Richard ^b  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Atypical pseudocholinesterase; BChE; Butyrylcholinesterase; Genetic variants; Pseudocholinesterase

Indexed keywords

ACETYLSALICYLIC ACID; BAMBUTEROL; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CINCHOCAINE; COCAINE; CYCLOPHOSPHAMIDE; ECOTHIOPATE; EDROPHONIUM; FLUORIDE; FRESH FROZEN PLASMA; METOCLOPRAMIDE; MIVACURIUM; NEOSTIGMINE; ORAL CONTRACEPTIVE AGENT; ORGANOPHOSPHATE INSECTICIDE; PANCURONIUM; PHENELZINE; PHYSOSTIGMINE; PYRIDOSTIGMINE; SUXAMETHONIUM; TACRINE; ANESTHETIC AGENT;

ALZHEIMER DISEASE; APNEA; BLOOD TRANSFUSION; BURN; CARDIOPULMONARY BYPASS; CHEMICAL ANALYSIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENETIC SCREENING; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; INHERITANCE; INTERNET; KIDNEY DISEASE; LEPROSY; LIVER DISEASE; MALNUTRITION; MEDLINE; NEOPLASM; PARALYSIS; POLYMERASE CHAIN REACTION; PREGNANCY; PSEUDOCHOLINESTERASE DEFICIENCY; REVIEW; DEFICIENCY; GENETICS; METABOLISM; NURSE ANESTHETIST;

ANESTHETICS; BUTYRYLCHOLINESTERASE; GENETIC VARIATION; HUMANS; NURSE ANESTHETISTS; PSEUDOCHOLINESTERASE;

EID: 77957681259     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Manoharan I, Wieseler S, Layer PG, Lockridge O, Boopathy R. Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India. Pharmacogenet Genomics. 2006;16 (7):461-468.
2. Manoharan I, Boopathy R, Darvesh S, Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta. 2007;378(l-2): 128-135. (Pubitemid 46251527)
3. Mikami LR, Wieseler S, Souza RL, et al. Five new naturally occurring mutations of the BCHE gene and frequencies of 12 butyrylcholinesterase alleles in a Brazilian population. Pharmacogenet Genomics. 2008;18(3):213-218.
4. Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Biochem Physiol. 1957;35(12):1305-1320.
5. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase: determination of dibucaine numbers. Surv Anesthesiol. 19;17(6):581-588.
6. Morgan GE, Mikhail MS, Murray MJ. Clinical Anesthesiology. 4th ed. New York, NY: McGraw-Hill; 2006:205-226.
7. Harris H, Whittaker, M. Differential inhibition of human serum cholinesterase with fluoride: recognition of two new phenotypes. Nature. 1961;191:496-498.
8. Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet. 1992;50(5): 1086-1103.
9. Jensen FS, Schwartz M, Viby-Mogensen J. Identification of human plasma cholinesterase variants using molecular biological techniques. Acta Anaesthesiol Scand. 1995;39(2): 142-149.
10. Iohom G, Fitzgerald D, Cunningham AJ. Principles of pharmacogenetics: implications for the anaesthetist. Br J Anaesth. 2004;93(3):440-450.
11. Aldrete JA, O'Higgins JW, Holmes J. Changes of plasma cholinesterase activity during orthotopic liver transplantation in man. Transplantation. 1977;23(5):404-406.
12. Mullan DP, Williams NE. Left-sided amoebic liver abscess with pulmonary involvement, pericarditis, and pseudocholinesterase deficiency. Br Med J. 1965;l(5429):235-236.
13. McQueen MJ. Clinical and analytical considerations in the utilization of cholinesterase measurements. Clin Chim Acta. 1995;237(1-2):91-105.
14. Whittaker M. Plasma cholinesterase variants and the anaesthetist. Anaesthesia. 1980;35(2):174-197.
15. Simon NM, Del Greco F, Dietz AA, Rubinstein HM. Serum cholinesterase deficiency in renal failure. Trans Am Soc Artif Intern Organs. 1969;15(l):328-332.
16. Bishop MJ, Hornbein TF. Prolonged effect of succinylcholine after neostigmine and pyridostigmine administration in patients with renal failure. Anesthesiology. 1983;58(4):384-386.
17. Ryan DW. Preoperative serum cholinesterase concentration in chronic renal failure: clinical experience of suxamethonium in 81 patients undergoing renal transplant. Br J Anaesth. 1977;49(9):945-949.
18. Ryan DW. Postoperative serum cholinesterase activity following successful renal transplantation. Br J Anaesth. 1979;51(9):881-884.
19. Barclay GP. Pseudocholinesterase activity as a guide to prognosis in malnutrition. Am J Clin Pathol. 1973;59(5):712-716.
20. Robertson GS. Serum cholinesterase deficiency: II. Pregnancy. Br J Anaesth. 1966;38(5):361-369.
21. Lurie S, Sadan O, Oron G, et al. Reduced pseudocholinesterase activity in patients with HELLP syndrome. Reprod Sci. 2007;14(2): 192-196. (Pubitemid 351168839)
22. Kaniaris P, Fassoulaki A, Liarmakopoulou K, Dermitzakis E. Serum cholinesterase levels in patients with cancer. Anesth Analg. 1979;58 (2):82-84. (Pubitemid 9189737)
23. Soreq H, Lapidot-Lifson Y, Zakut H. A role for cholinesterases in tumorigenesis? Cancer Cells. 1991;3(12):511-516.
24. Viby-Mogensen J, Hanel HK, Hansen E, Sorensen B, Graae J. Serum cholinesterase activity in burned patients: I. Biochemical findings. Acta Anaesthesiol Scand. 1975;19(3):159-168.
25. Rump AF, Schierholz J, Biederbick W et al. Pseudocholinesterase-activity reduction during cardiopulmonary bypass: the role of dilutional processes and pharmacological agents. Gen Pharmacol. 1999;32 (l):65-69. (Pubitemid 28540792)
26. Navarrete JI, Lisker R, Perez-Briceno R. Serum atypical pseudocholinesterase and leprosy. Int J Dermatol. 1979;18(10):822-823.
27. McGavi DD. Depressed levels of serum-pseudocholinesterase with ecothiophate-iodide eyedrops. Lancet. 1965;2(7406):272-273.
28. Kamha AA, Al Omary IY, Zalabany HA, Hanssens Y, Adheir FS. Organophosphate poisoning in pregnancy: a case report. Basic Clin Pharmacol Toxicol. 2005;96(5):397-398.
29. Nelson TC, Burritt MF. Pesticide poisoning, succinylcholine-induced apnea, and pseudocholinesterase. Mayo Clin Proc. 1986;61(9):750-752.
30. Purdham RS, Gutierrez DS. Pseudocholinesterase deficiency and organophosphorous insecticide use. AANA J. 1986;54(3):240-244.
31. Sener EB, Ustun E, Kocamanoglu S, Tur A. Prolonged apnea following succinylcholine administration in undiagnosed acute organophosphate poisoning. Acta Anaesthesiol Scand. 2002;46(8): 1046-1048.
32. Koseoglu V, Chiang J, Chan KW Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. Bone Marrow Transplant. 1999;24(12): 1367-1368. (Pubitemid 30052797)
33. Sprung J, Castellani WJ, Srinivasan V, Udayashankar S. The effects of donepezil and neostigmine in a patient with unusual pseudocholinesterase activity. Anesth Analg. 1998;87(5):1203-1205. (Pubitemid 28501187)
34. Sunew KY, Hicks RG. Effects of neostigmine and pyridostigmine on duration of succinylcholine action and pseudocholinesterase activity. Anesthesiology. 1978;49(3):188-191.
35. Ramirez JG, Sprung J, Keegan MT, Hall BA, Bourke DL. Neostigmine-induced prolonged neuromuscular blockade in a patient with atypical pseudocholinesterase. J Clin Anesth. 2005;17(3):221-224.
36. Bevan DR, Donati F. Succinylcholine apnoea: attempted reversal with anticholinesterases. Can Anaesth Soc J. 1983;30(5):536-539.
37. McCaul K, Robinson GD. Suxamethonium "extension" by tetrahydroaminacrine. Br J Anaesth. 1962;34:536-542.
38. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldrank LR. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emerg Med. 1992;21(3):247-253.
39. Sosolceva M, Stojanova S, Kalinikov R, Trojic T. Pseudocholinesterase activity at surgical population: new aspects [abstract]. Acta Anaesthesiol Scand. 1999;43(suppl 114):99.
40. Robertson GS. Serum protein and cholinesterase changes in association with contraceptive pills. Lancet. 1967;l(7484):232-235.
41. Bodley PO, Halwax K, Potts L. Low serum pseudocholinesterase levels complicating treatment with phenelzine. Br Med J. 1969;3(5669): 510-512.
42. Stovner J, Oftedal N, Holmboe J. The inhibition of cholinesterases by pancuronium. Br J Anaesth. 1975;47(9):949-954.
43. Motamed C, Fanen P, Feiss P, Kirov K, Duvaldestin P. Dose-response effect of serum butyrylcholinesterase activity after clinical doses of pancuronium. Eur J Clin Pharmacol. 2008;64(11): 1043-1045.
44. Ostergaard D, Rasmussen SN, Viby-Mogensen J, Pedersen NA, Boysen R. The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. Anesthesiology. 2000;92(6):1581-1587.
45. Valentino RJ, Lockridge O, Eckerson HW, La Du BN. Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies. Biochem Pharmacol. 1981;30(12):1643-1649. (Pubitemid 11072296)
46. Kao YJ, Turner DR. Prolongation of succinylcholine block by metoclopramide. Anesthesiology. 1989;70(6):905-908.
47. Lovely MJ, Patteson SK, Beuerlein FJ, Chesney JT. Perioperative blood transfusion may conceal atypical pseudocholinesterase. Anestk Analg. 1990;70(3):326-327.
48. Smith DC, Ridley SA, Donaldson KF. Fresh frozen plasma and edrophonium in a patient with a plasma cholinesterase deficiency. Anaesthesia. 1993;48(6):511-513.
49. Gill RS, O'Connell N, Scott RP. Reversal of prolonged suxamethonium apnoea with fresh frozen plasma in a 6-week-old infant. Anaesthesia. 1991;46(12):1036-1038.
50. Ostergaard D, Jensen FS, Viby-Mogensen J. Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase. Anesthesiology. 1995;82(5):1295-1298.
51. GeneTests website, http://www.genetests.org. Accessed June 1, 2010.
52. OMIM - Online Mendelian Inheritance in Man website. http://www ncbi.nlm.nih.gov/sites/entrez?db=OMIM. Accessed June 1, 2010.